Last reviewed · How we verify
RBM-007 Injectable Solution
At a glance
| Generic name | RBM-007 Injectable Solution |
|---|---|
| Sponsor | Ribomic USA Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration (PHASE2)
- A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration (PHASE2)
- RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration (PHASE1, PHASE2)
- RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RBM-007 Injectable Solution CI brief — competitive landscape report
- RBM-007 Injectable Solution updates RSS · CI watch RSS
- Ribomic USA Inc portfolio CI